Joe Rogan on vioxx: what the evidence says · JRE #2335

FACT CHECK // JRE #2335 // EXHIBIT LOG
EPISODE AIRED JUN 10, 2025 · THE JOE ROGAN EXPERIENCE
CLAIM CMRGC51QSTATUS: PUBLISHED
SUBJECT: VIOXX
SpeakerJoe Rogan (host)
Timestamp48:51
Aired
RulingNeeds Context

Not a true/false call. Every claim is logged with its sources; read the exhibits below.

// THE CLAIM · ON TAPE
In the emails that were admitted during the hearings when they lost or during the court proceedings They wound up paying a fraction of what they made they made like 12 billion dollars
Joe Roganhost@ 48:51
Watch on YouTubeJUMP TO 48:51

What the evidence says 01 / RECORD

Merck's arthritis painkiller Vioxx (rofecoxib) was on the market from May 1999 until its withdrawal in September 2004, and peer-reviewed sources report it brought in more than 2.5 billion dollars annually, roughly 10 percent of Merck's worldwide sales, at its peak. Over its roughly five years on sale that implies cumulative revenue in the range of about 10 to 12 billion dollars, so Rogan's 12 billion figure is at the high end but in the right ballpark. In November 2007 Merck agreed to pay a fixed 4.85 billion dollars to settle 26,600 lawsuits representing 47,000 plaintiffs over heart attack and stroke claims. That settlement was indeed a fraction of the drug's lifetime sales, supporting the core of the claim. Roughly accurate.

/// factcheckjoerogan.com